An interventional study of DE-CTPA with 30 mL iomeprol 300 mg I/mL and DE-CTPA with 50 mL iomeprol 300 mg I/mL in Pulmonary Embolism, sponsored by Wuxi People's Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 97 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Wuxi People's Hospital · Not applicable, Interventional, and Diagnostic
Among 72 studies in Pulmonary Embolism with a site in China — 26 open to participants now, 31 under way, 1 of them phase 3. Pulmonary Embolism · China.
Among the 72 studies in Pulmonary Embolism with a site in China, this one is the 10th largest by enrollment of the 33 interventional ones, is one of 5 that started in 2023, is one of 14 with no phase, and was the 50th registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
This study's enrollment of 2,216 is above the median of 174 across 429 interventional studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →26 of the 72 studies in Pulmonary Embolism with a site in China are open now, in 1 country. Each count lists the studies.
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 97 Years · all sexes · no healthy volunteers.
The full table on the hub →72 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2023.
Median enrollment 417 across the 33 interventional studies, 1,000 across the 39 observational. Of the 28 that completed or were terminated, 7 (25%) have results posted.
15 of 72 have an industry lead sponsor. The 10 most frequent:
Wuxi People's Hospital is the lead sponsor of 16 studies on the registry; 5 are open to participants now.
Wuxi People's Hospital has 1 study filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
9 of the studies in Pulmonary Embolism with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT06596941Ruijin HospitalUltrasound Assessment of Isolated Distal Deep Vein Thrombosis | 2026-12-31 |
| NCT05482269Shengjing HospitalAdverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography | 2026-12-31 |
| NCT05098769Shengjing HospitalA Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA. | 2026-12-31 |
| NCT06341231Xiangya Hospital of Central South UniversityPersonalized Anticoagulant Therapy for Pulmonary Thromboembolism | 2026-12-31 |
Among the 72 studies in Pulmonary Embolism with a site in China, from their registry updates:
The investigators aimed to compare the image quality and diagnostic performance of DECTPA using lower concentration iodine contrast materials and using normal concentration iodine contrast materials in the evaluation of suspected pulmonary embolism.
All patients met the inclusion and exclusion criteria will be given written informed consensus. The enrolled patients will randomly receive one of the three injection protocols: A: 30mL Iomeprol (Iomeron, 300 mg I/mL; Bracco Imaging Italia S.r.l., Milan, Italy) injected at a flow rate of 4mL/s; B: 50mL Iomeprol (Iomeron, 300 mg I/mL; Bracco Imaging Italia S.r.l., Milan, Italy) injected at a flow rate of 4mL/s; C: 50mL Ioversol (Ioversol, 350mg I/mL, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu, China) injected at a flow rate of 4mL/s. A and B groups are both lower concentration iodine contrast material groups, with different total iodine loads.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 30 mL of iomeprol (300 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Diagnostic Test: DE-CTPA with 30 mL iomeprol 300 mg I/mL
Participants received 50 mL of iomeprol (300 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Diagnostic Test: DE-CTPA with 50 mL iomeprol 300 mg I/mL
Participants received 50 mL of Ioversol (350 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Diagnostic Test: DE-CTPA with 50 mL Ioversol 350 mg I/mL
Dual-energy CTPA was performed after intravenous administration of 30 mL of iomeprol (300 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Dual-energy CTPA was performed after intravenous administration of 50 mL of iomeprol (300 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Dual-energy CTPA was performed after intravenous administration of 50 mL of Ioversol (350 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Pulmonary arterial attenuation on CTPA
Pulmonary arterial attenuation was measured in Hounsfield units (HU) at predefined pulmonary arterial levels.
Time frame: Baseline (during the CTPA examination)
Image noise on CTPA
Image noise was quantified as the standard deviation of CT attenuation values within predefined regions of interest, expressed in Hounsfield units (HU).
Time frame: Baseline (during the CTPA examination)
Signal-to-noise ratio (SNR) on CTPA
The signal-to-noise ratio (SNR) was calculated as the mean vascular attenuation divided by image noise. SNR is a dimensionless measure.
Time frame: Baseline (during the CTPA examination)
Contrast-to-noise ratio (CNR) on CTPA
The contrast-to-noise ratio (CNR) was calculated as the difference in mean CT attenuation between the pulmonary artery and reference tissue divided by image noise. CNR is a dimensionless measure.
Time frame: Baseline (during the CTPA examination)
Subjective image quality score on CTPA
Diagnostic image quality was assessed using a 5-point ordinal scale, ranging from 1 (poorest image quality) to 5 (best image quality), with higher scores indicating better image quality.
Time frame: Baseline (during the CTPA examination)
Diagnostic accuracy of CTPA for pulmonary embolism
Diagnostic accuracy was calculated as the proportion of correctly classified cases (true positives and true negatives) among all evaluable cases, using the reference standard for pulmonary embolism diagnosis. Results were expressed as percentages (%).
Time frame: Baseline (during the CTPA examination)
Sensitivity of CTPA for pulmonary embolism
Sensitivity was calculated as the proportion of true-positive cases among all cases with pulmonary embolism confirmed by the reference standard. Results were expressed as percentages (%).
Time frame: Baseline (during the CTPA examination)
Specificity of CTPA for pulmonary embolism
Specificity was calculated as the proportion of true-negative cases among all cases without pulmonary embolism according to the reference standard. Results were expressed as percentages (%).
Time frame: Baseline (during the CTPA examination)
Diagnostic accuracy for isolated SSPE
Diagnostic accuracy was calculated as the proportion of correctly classified cases (true positives and true negatives) among all evaluable cases, using the reference standard for isolated subsegmental pulmonary embolism (SSPE). Results were expressed as percentages (%).
Time frame: Baseline (during the CTPA examination)
Sensitivity of CTPA for isolated subsegmental pulmonary embolism
Sensitivity was calculated as the proportion of true-positive cases among all cases with isolated subsegmental pulmonary embolism (SSPE) confirmed by the reference standard. Results were expressed as percentages (%).
Time frame: Baseline (during the CTPA examination)
Specificity of CTPA for isolated subsegmental pulmonary embolism
Specificity was calculated as the proportion of true-negative cases among all cases without isolated subsegmental pulmonary embolism (SSPE) according to the reference standard. Results were expressed as percentages (%).
Time frame: Baseline (during the CTPA examination)
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Dec 2025, 27 months.
Of 125 non-industry interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 27 months is close to that.
Counting every sponsor, half of 150 studies reached it within 25 months; a quarter within 15 and three quarters within 51.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Nov 2024 → Dec 2025 and completion Jun 2025 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wuxi People's Hospital